Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00166127 · ClinicalTrials.gov registry record · Phase 3
Study of Blood Concentrations and Physiologic Effects of Levosimendan Given During Heart Surgery
A Phase 3 study, sponsored by Emory University.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1
- Enrollment target
NCT00166127 is a Phase 3 study that was terminated before completion, run by Emory University. The registered enrollment target is 1 participants.
The verdict
NCT00166127, a Phase 3 study, was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study protocol is to evaluate the blood concentrations of levosimendan when administered at different doses clinically employed during cardiopulmonary bypass or cardiac manipulation during off pump surgery in patients who require the drug for inotropic support (improved heart function) and the associated hemodynamic variables (vital signs). Levosimendan is one of the first agents in a new class of drugs used to treat heart failure and works via a unique mechanism called calcium sensitization, that makes the heart beat more efficiently. Levosimendan also has unique effects on the blood vessels, as well as causing relaxation, an important therapeutic approach of heart failure therapy.
Interventions
- DRUG Levosimendan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2005-05 |
| Est. Completion | 2007-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00166127
The ClinicalTrials.gov registry entry for NCT00166127 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Levosimendan is the first listed.
NCT00166127 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00166127 about?
NCT00166127 is a clinical study titled "Study of Blood Concentrations and Physiologic Effects of Levosimendan Given During Heart Surgery". The purpose of this study protocol is to evaluate the blood concentrations of levosimendan when administered at different doses clinically employed during cardiopulmonary bypass or cardiac manipulation during off pump surgery in patients who require the drug for inotropic support (improved heart fun...
What is the current status of trial NCT00166127?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1 participants. The study started on 2005-05. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00166127?
The interventions under investigation include: Levosimendan (DRUG).
Who is sponsoring clinical trial NCT00166127?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.